Venture money flowing into women's health startups hit a high point in 2024 — and then pulled back. According to BioPharma Dive, investment in the space declined last year after that 2024 peak, leaving founders and funders asking what it would take to turn the trend around.
The answer some in the industry are offering is a "reset." BioPharma Dive reports that two forces in particular are being floated as potential catalysts for a rebound: broader adoption of AI across the sector, and a widening definition of what actually counts as women's health.
Both are worth unpacking. AI adoption in a research-heavy, capital-hungry field can change the math on how quickly a small company gets from an idea to something investors can evaluate — which matters most in exactly the kind of tight funding environment the sector is now in.
The second shift is arguably bigger. "Women's health" has traditionally been read narrowly, clustered around reproductive care. A widening definition pulls in a much larger set of conditions and, with it, a much larger addressable market — the kind of expansion that changes how a venture investor sizes an opportunity.
It's worth being clear about what the reporting does and doesn't establish. BioPharma Dive frames the rebound as something "some say" could happen, drawing on an SVB report — a forecast from interested parties, not a rebound that has already been measured.
This matters because women's health has long been underfunded relative to how many people it affects, and a sustained pullback in venture dollars now would slow the pipeline of treatments and diagnostics reaching patients years down the line.